Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
HCW Biologics Inc. entered into Securities Purchase Agreement with a single institutional investor valued at approximately $1.5 million (effective 2026-02-17).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- a single institutional investor
- Value
- approximately $1.5 million
- Effective
- 2026-02-17
Exact text from the filing
On February 17, 2026, HCW Biologics Inc. (the “Company”) entered into a securities purchase agreement (“SPA”) with a single institutional investor (the "Purchaser") pursuant to which the Company agreed to offer and sell, in a follow-on public offering (the “Offering”), 2,477,292 units
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
HCW Biologics Inc. entered into Placement Agency Agreement with Maxim Group LLC (effective 2026-02-17).
- Action
- entry
- Agreement
- underwriting
- Counterparty
- Maxim Group LLC
- Effective
- 2026-02-17
Exact text from the filing
On February 17, 2026, the Company entered into a placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (“Maxim” or the “Placement Agent”) pursuant to which the Company engaged the Placement Agent as the exclusive placement agent in connection with the Offering.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
HCW Biologics Inc. entered into Existing Warrants Amendment Agreement with the Purchaser (effective 2026-02-17).
- Action
- entry
- Counterparty
- the Purchaser
- Effective
- 2026-02-17
Exact text from the filing
On February 17, 2026, the Company also entered into a privately negotiated agreement with the Purchaser, which holds certain existing outstanding warrants to purchase up to 3,020,410 shares of Common Stock (the “Prior Warrants”) to seek stockholder approval in accordance with applicable Nasdaq rules to reduce the exercise price of such Prior Warrants to the public offering price per Unit paid in the Offering (the “Existing Warrants Amendment Agreement”).
View on SEC.gov